# US 2008/0188927 A1 · Endovascular implant with active coating > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0188927 A1 - Document ID: US20080188927A1 - Status: Published application - Kind: A1 - Application number: 11/951,620 - Filed: 2007-12-06 - Published: 2008-08-07 - Earliest claimed: 2002-08-13 - Assignees: Biotronik Mess-und Therapiegeraete GmbH & Co. - Inventors: Roland Rohde; Katrin Sternberg; Tobias Diener - Web page: https://patentgrep.com/patent/US20080188927A1 ## CPC - A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} - A61F 2/91: made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes - A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus - A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) ## Abstract The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPARα-agonists, PPARδ-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists. ## Claims ### Claim 1 An endovascular implant, comprising: an active coating comprising a combination of PPARδ-agonists and RXR-agonists as an active substance on at least a portion of the endovascular implant. ### Claim 2 (depends on 1) The implant of claim 1, wherein: the active substance further comprises a fibrate from the group consisting of clofibrate, etofibrate, etofyllinclofibrate, bezafibrate, fenofibrate and gemfibrozil. ### Claim 3 (depends on 2) The implant of claim 2, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 4 (depends on 1) The implant of claim 1, wherein: the active substance further comprises a glitazone from the group consisting of ciglitazone, pioglitazone, rosiglitazone and troglitazone. ### Claim at position 5 (depends on 4) 5 The implant of claim 4, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 6 (depends on 1) The implant of claim 1, wherein: the active substance further comprises bexarotene or phytanic acid. ### Claim 7 (depends on 6) The implant of claim 6, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 8 (depends on 1) The implant of claim 1, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 9 An endovascular implant, comprising: an active coating comprising a PPARδ-agonist as an active substance on at least a portion of the endovascular implant. ### Claim 10 (depends on 9) The implant of claim 9, wherein: the active substance further comprises a fibrate from the group consisting of clofibrate, etofibrate, etofyllinclofibrate, bezafibrate, fenofibrate and gemfibrozil. ### Claim 11 (depends on 10) The implant of claim 10, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 12 (depends on 9) The implant of claim 9, wherein: the active substance further comprises a glitazone from the group consisting of ciglitazone, pioglitazone, rosiglitazone and troglitazone. ### Claim 13 (depends on 12) The implant of claim 12, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 14 (depends on 9) The implant of claim 9, wherein: the active substance further comprises bexarotene or phytanic acid. ### Claim 15 (depends on 14) The implant of claim 14, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 16 (depends on 9) The implant of claim 9, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 17 An endovascular implant, comprising: an active coating comprising an RXR-agonist as an active substance on at least a portion of the endovascular implant. ### Claim 18 (depends on 17) The implant of claim 17, wherein: the active substance further comprises bexarotene or phytanic acid. ### Claim 19 (depends on 18) The implant of claim 18, wherein: the active coating further comprises a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid. ### Claim 20 (depends on 17) The implant of claim 17, wherein: the active coating further a drug carrier from the group consisting of polylactide, poly-L-lactide and hyaluronic acid.